Because Zepbound is FDA-approved, the SURMOUNT-1 trial result (22.5% mean weight loss with 15mg tirzepatide over 72 weeks) applies to it unlike compounded tirzepatide, which is not FDA-approved and has not been evaluated at that trial scale
Beyond blood sugar management, GLP-1 can positively impact your digestive process and appetite regulation
GLP-1 provides powerful appetite suppression and gastric slowing
Its also important to track outcomes honestly and over an appropriate time frame
Healthcare providers can assess whether symptoms represent medication adverse effects, complications of treatment, or unrelated medical conditions requiring specific intervention
Clinical investigations further confirmed that GLP-1RA treatment led to significant improvements in key pulmonary function parameters, including forced expiratory volume in one second (FEV 1 ), forced vital capacity (FVC), and mid-expiratory flow rates (MEF 75 and MEF 50 )